Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Agios Pharmaceuticals to Present at the UBS Global Life Sciences Conference

Cambridge, Mass. – September 13, 2012 – Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 20, 2012 at 2:30PM EST at the Grand Hyatt in New York City.

Dr. Schenkein is expected to discuss the company’s portfolio of cancer metabolism therapeutics, its expansion into targeting inborn errors of metabolism, and the assets and capabilities that position Agios as a leader in dysregulated metabolism.

About Agios Pharmaceuticals

Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic, in addition to an active research and discovery pipeline across both therapeutic areas. The company has a significant collaboration with Celgene focused on developing new treatments for cancer leveraging Agios’ capabilities and insights into cancer metabolism. For more information, please visit our website at www.agios.com.